This insight brief examines chronic cough as a prevalent and debilitating symptom in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis and scleroderma-associated ILD. It highlights the significant impact on patients’ physical functioning, emotional well-being, and quality of life, as well as its potential role as an early indicator of disease progression. The brief discusses current understanding of the multifactorial mechanisms driving chronic cough in ILD, including fibrosis-related changes, airway hypersensitivity, and neurogenic pathways. It also reviews gaps in current management, as effective treatment options remain limited. Emerging innovations are explored, including novel therapeutic targets, improved patient-reported outcome measures, and adv

Join for free to read